Novavax Analyst Says Coronavirus Vaccine 'Promising': 6 Takeaways From Phase 1 Results
Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer
Novavax Analyst 'Encouraged' By Preclinical Data For Coronavirus Vaccine Candidate
Novavax Analyst Says DoD Funding Reflects Conviction In Platform, Ability To Deliver On Vaccine
Charles Duncan Recent News
Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race
Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine
A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio
10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia
Analysts Remain Upbeat On GW Pharma's Optionality With Epidiolex
Cantor Fitzgerald's 7 Buys For 7 Biotechs
Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response
Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain
The Street May Be Underappreciating Alder Biopharma's Phase 3 Data
Piper Jaffray Defends Alder Despite Stock Slump, Looks To What's Next In Migraine Management
Piper Jaffray Sees Strength In Geron After News Of Drug Development
On Wall Street, Questions Remain For Conatus Pharma
Acadia Pharma May No Longer Be A Buy Ahead Of NDA Filing
Why Piper Jaffray's Charles Duncan Still Likes Catalyst Pharmaceuticals
Shares of Vivus Fall +10% Following Piper Jaffray's Downgrade
Geron Revealed Positive Imetelstat Results Amidst Data Concerns